<SEC-DOCUMENT>0001193125-14-048514.txt : 20140213
<SEC-HEADER>0001193125-14-048514.hdr.sgml : 20140213
<ACCEPTANCE-DATETIME>20140212175300
ACCESSION NUMBER:		0001193125-14-048514
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20140213
DATE AS OF CHANGE:		20140212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-187508
		FILM NUMBER:		14601770

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d676653d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<DIV STYLE="position:relative;float:left; margin-right:1%; width:48%;padding-right:9pt;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus Supplement No. 15 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated May&nbsp;30, 2013)
</B></P></DIV><DIV STYLE="position:relative;float:right; width:48%;padding-right:9pt;padding-bottom:8pt;overflow:hidden;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424 (b)(4) <BR> Registration No. 333-187508<BR><BR>
</B></P></DIV><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>125,000 Shares of Series A Convertible Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>12,500,000 Shares of Common Stock Underlying the Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase up to 6,250,000 Shares of Common Stock and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>6,250,000 Shares of Common Stock Underlying the Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g676653tx_pg001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement supplements the prospectus dated May&nbsp;30, 2013 (the &#147;Prospectus&#148;), as supplemented by that certain
Prospectus Supplement No.&nbsp;1 dated July&nbsp;17, 2013 (&#147;Supplement No.&nbsp;1&#148;), by that certain Prospectus Supplement No.&nbsp;2 dated July&nbsp;19, 2013 (&#147;Supplement No.&nbsp;2&#148;), by that certain Prospectus Supplement
No.&nbsp;3 dated July&nbsp;24, 2013 (&#147;Supplement No.&nbsp;3&#148;), by that certain Prospectus Supplement No.&nbsp;4 dated July&nbsp;30, 2013 (&#147;Supplement No.&nbsp;4&#148;), by that certain Prospectus Supplement No.&nbsp;5 dated
August&nbsp;6, 2013 (&#147;Supplement No.&nbsp;5&#148;), by that certain Prospectus Supplement No.&nbsp;6 dated September&nbsp;4, 2013 (&#147;Supplement No.&nbsp;6&#148;), by that certain Prospectus Supplement No.&nbsp;7 dated September&nbsp;23,
2013 (&#147;Supplement No.&nbsp;7&#148;), by that certain Prospectus Supplement No.&nbsp;8 dated October&nbsp;29, 2013 (&#147;Supplement No.&nbsp;8&#148;), by that certain Prospectus Supplement No.&nbsp;9 dated November&nbsp;6, 2013
(&#147;Supplement No.&nbsp;9&#148;), by that certain Prospectus Supplement No.&nbsp;10 dated November&nbsp;13, 2013 (&#147;Supplement No.&nbsp;10&#148;), by that certain Prospectus Supplement No.&nbsp;11 dated November&nbsp;21, 2013
(&#147;Supplement No.&nbsp;11&#148;), by that certain Prospectus Supplement No.&nbsp;12 dated December&nbsp;5, 2013 (&#147;Supplement No.&nbsp;12&#148;), by that certain Prospectus Supplement No.&nbsp;13 dated January&nbsp;8, 2014 (&#147;Supplement
No.&nbsp;13&#148;), and by that certain Prospectus Supplement No.&nbsp;14 dated February&nbsp;10, 2014 (&#147;Supplement No.&nbsp;14&#148;, and together with Supplement No.&nbsp;1, Supplement No.&nbsp;2, Supplement No.&nbsp;3, Supplement No.&nbsp;4,
Supplement No.&nbsp;5, Supplement No.&nbsp;6, Supplement No.&nbsp;7, Supplement No.&nbsp;8, Supplement No.&nbsp;9, Supplement No.&nbsp;10, Supplement No.&nbsp;11, Supplement No.&nbsp;12, and Supplement No.&nbsp;13, the &#147;Supplements&#148;),
which form a part of our Registration Statement on Form S-1 (Registration No.&nbsp;333-187508). This prospectus supplement is being filed to update and supplement the information in the Prospectus and the Supplements with the information contained
in our current report on Form 8-K, filed with the Securities and Exchange Commission (the &#147;Commission&#148;) on February&nbsp;12, 2014 (the &#147;Current Report&#148;). Accordingly, we have attached the Current Report to this prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus, the Supplements and this prospectus supplement relate to the offer and sale of up to 125,000 shares of Series
A Convertible Preferred Stock (&#147;Preferred Stock&#148;) which are convertible into 12,500,000 shares of Common Stock, warrants to purchase up to 6,250,000 shares of our Common Stock and 6,250,000 shares of Common Stock underlying the warrants.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement should be read in conjunction with the Prospectus and the Supplements. This prospectus supplement updates and
supplements the information in the Prospectus and the Supplements. If there is any inconsistency between the information in the Prospectus, the Supplements and this prospectus supplement, you should rely on the information in this prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Global Market under the trading symbol &#147;ABIO.&#148; On February&nbsp;12, 2014,
the last reported sale price of our common stock was $1.79 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in
our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;Risk Factors&#148; beginning on page 5 of the Prospectus and beginning on page 23 of our quarterly report on
Form 10-Q for the quarterly period ended September&nbsp;30, 2013 before you decide whether to invest in shares of our common stock. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is February&nbsp;12, 2014 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section 13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): February&nbsp;12, 2014 (February 11, 2014) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-22873</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>36-3855489</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11080 CirclePoint Road, Suite 140, Westminster, CO 80020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(720) 940-2200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;11, 2014, the Board of Directors (the &#147;Board&#148;) of
ARCA biopharma, Inc. (the &#147;Company&#148;) elected Daniel J. Mitchell as a director of the Company to fill a vacancy on the Board. Mr.&nbsp;Mitchell was elected for a term expiring at the Company&#146;s 2015 annual stockholders&#146; meeting.
Mr.&nbsp;Mitchell was also appointed to serve on the Board&#146;s Audit Committee and Nominating and Corporate Governance Committee. A copy of the press release announcing Mr.&nbsp;Mitchell&#146;s appointment is attached hereto as Exhibit 99.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Mitchell founded and is a Manager of Sequel Venture Partners, L.L.C., a venture capital firm formed in January 1997. Prior to
founding Sequel Venture Partners, Mr.&nbsp;Mitchell was a founder in 1986 of Capital Health Venture Partners, a health care focused venture capital firm, where he was a General Partner until 2006. On behalf of Sequel Ventures, Mr.&nbsp;Mitchell led
the 1998 Series A financing that initially funded Myogen, Inc., a biopharmaceutical company focused on cardiovascular diseases, participated in subsequent financing rounds and served on the board of directors until Myogen was acquired in 2006. He
served on the board of directors of Replidyne, Inc., a publicly-traded pharmaceutical company, from 2002 until the company was acquired in 2009. Mr.&nbsp;Mitchell currently serves on the board of directors of several private companies.
Mr.&nbsp;Mitchell holds a B.S. from the University of Illinois and an M.B.A. from the University of California at Berkeley. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection
with Mr.&nbsp;Mitchell&#146;s election, Mr.&nbsp;Mitchell and the Company entered into an Indemnity Agreement, in the same form used with the Company&#146;s other directors.&nbsp;The Indemnity Agreement generally requires the Company to indemnify
Mr.&nbsp;Mitchell against liabilities incurred in the performance of his duties to the Company to the maximum extent permitted by Delaware corporate law and the Company&#146;s certificate of incorporation and bylaws.&nbsp;The Company&#146;s standard
form of Indemnity Agreement is filed as Exhibit&nbsp;10.52 to its Annual Report on Form 10-K filed on March&nbsp;27, 2009. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9 &#151;
Financial Statements and Exhibits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;Dan Mitchell Joins ARCA biopharma Board of Directors&#148; dated February 12, 2014.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: February&nbsp;12, 2014 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARCA biopharma, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Christopher D. Ozeroff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Christopher D. Ozeroff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">SVP and General Counsel</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;Dan Mitchell Joins ARCA biopharma Board of Directors&#148; dated February 12, 2014.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g676869g91g31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DAN MITCHELL JOINS ARCA BIOPHARMA BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Westminster, CO, February&nbsp;12 2014</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted
therapies for cardiovascular diseases, today announced that Dan Mitchell has been appointed to the Company&#146;s Board of Directors. He will serve on the Audit and Nominating and Corporate Governance Committees of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Mitchell founded and is a Manager of Sequel Venture Partners, L.L.C., a venture capital firm formed in January 1997. Prior to founding Sequel Venture
Partners, Mr.&nbsp;Mitchell was a founder in 1986 of Capital Health Venture Partners, a health care focused venture capital firm, where he was a General Partner until 2006. On behalf of Sequel Ventures, Mr.&nbsp;Mitchell led the 1998 Series A
financing that initially funded Myogen, Inc., a biopharmaceutical company focused on cardiovascular diseases, participated in subsequent financing rounds and served on the board of directors until Myogen was acquired in 2006. He served on the board
of directors of Replidyne, Inc., a publicly-traded pharmaceutical company, from 2002 until the company was acquired in 2009. Mr.&nbsp;Mitchell currently serves on the board of directors of several private companies. Mr.&nbsp;Mitchell holds a B.S.
from the University of Illinois and an M.B.A. from the University of California at Berkeley. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are honored to have Dan join the ARCA Board of
Directors,&#148; said Dr.&nbsp;Michael&nbsp;R. Bristow, President and Chief Executive Officer of ARCA. &#147;With his significant expertise and experience in identifying investment worthy companies and helping to advise those companies in managing
their growth, Dan will be a valuable addition to the ARCA Board as we continue the development of Gencaro and look to deliver value to our stockholders.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am delighted to join the Board of ARCA at this important point in its development,&#148; said Mr.&nbsp;Mitchell. &#147;The imminent initiation of the
GENETIC-AF trial evaluating ARCA&#146;s Gencaro as potentially the first genetically-targeted atrial fibrillation prevention treatment is a tremendous step in hopefully addressing what we believe is an unmet medical need for new atrial fibrillation
treatments. ARCA&#146;s personalized medicine approach to drug development has identified both the compound and the regulatory pathway to potentially achieve that goal.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ARCA biopharma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA biopharma is dedicated to
developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (bucindolol hydrochloride), is an investigational, pharmacologically
unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first
genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information please visit <U>www.arcabiopharma.com</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to, statements regarding, potential timing for patient enrollment in the GENETIC-AF trial, the sufficiency of the Company&#146;s capital to support its operations, the potential for genetic
variations to predict individual patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, the role of AF burden in diagnosis and treatment of atrial
fibrillation and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and
performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether
they will be sufficient to meet the Company&#146;s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s
intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s
filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2012, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derek Cole </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">720.940.2163 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>derek.cole@arcabiopharma.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g676653tx_pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g676653tx_pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`00"T`P$1``(1`0,1`?_$`*L```$$`@,!````````
M``````D`!@<(!0H"`P0!`0$!`0`!!0$!`````````````0('`P4&"`D$"A``
M`00!`P,"!`4"!0,%`````0(#!`4&`!$'(1((,1-!(A0)42,5%A<R"F%Q@4(S
M\+$DP?%28A@1``$#`@4"!`4!!P`+``````$`$0(#!"$Q01(%!@=182(3<8$R
M%`B1\*&QP4(5%M'A4F*"DB-#4Y,E_]H`#`,!``(1`Q$`/P#=LY^\B\:X&JHK
MUI%?N;^X6MJ@QV$M"9,TH1W/2Y#BB4Q8,4_\BU;?@G<ZX$[\]_\`I/L1T_3Y
M7G-U?D;B>RC0@6))R,L#A\%Y9TCT?RG6%_\`:V&T48?63G_PH?C?GOSI:RE_
MIV*8;%;67`U&4Q93O;/>H-MKEMJ0A3GM*25#;;NW&OGE=?GMWDO.1J4>(LN$
MA0+SIPG&H9^WH)>O/S89KG6/9CIBA1`O:UT+D8RQB,-<&69C^9_D0\A]TT>!
MA#>WMH$&T#A4LI`0L*>^7L[MR3MTU^FV_-[\@+JA*K'CN$$H%R!3JGT_\QSS
M7YI=I^BHU(O<76V3X;H>/P6-F><7D)7);7*Q[!4MJ=`]PQ++M<;22'5,]CJP
M0!L1N>FOPU?SL[[VH%2]L^#ITI2<?].KNVZ#&39KK4>SW1]8^FXNBSN-T/EH
MIPX/\ZH^99!!PODBIK\;N;26F%5WT"47*.5,=1[C,&6R\$R83SNX2E8[T$_'
M7LAV%_-KB.XO4E'M[UG0^SZMKAX5J<=MO+6,?67$B&^:X_ZT[77'`TS><0:E
M:R9VDQD/%R-/#!$08<]U.Y6E1!/]/0`?@?7?;\=>_$*DI2,)!C^V.'BN(6(P
M.$EZ-=0!D3/SC,Z7C[%,FS;)YS%=C>'T-ED=_8+4HB#5U45V;,D+;2"M:6XS
M*B$I!4M6P`ZZ.'9$U.$N:,$\@N+\*YAXPN4Y#Q_R!3-7F,W;;+L5<J"ZZM@"
M3#?0E^%+;>94E;2_F01UUHMHBE5U?8A2]_Z$J)]0``%;=VVYZD?#XZB*F7,_
MW!?$CQTSM?''.7,E+QOE*8,*S6UD5==Q:IJ#9ESZ!3EZFN=ITN/):(`][<$=
M0-]-KZHHQG?=P^W7$0TEKRJXYGRY'N?30*==G=6;_LK"70S6UL"1*<*#T/R^
MIT9O-$\.-_N8^#G+>2Q\-PGR/X[=RV4"&<9R";*Q2Z>7[B6TMLP\BBUSKCJE
MJV"4@DD=-$.`W')7FCRVY(04'<.-H>0H$*0XTM(4AQM:24*0KX$="/31-'\5
M]>?4@A#827-BHA1^0#X!U0W]L*'H=O71%1_F_P"X_P"'7CYD+6%\B<V8ZYGS
MJRECCK"F+#/L\?Z#=)QO%(MG.96DG_<D:,^K(H%L?O*^(>.(=FY[7\_<:8ZV
M@O#+,ZX`Y*I<;=C@=WO_`*DNC4([7:0>YQ*1OTU6$=75#-CFK4^-OG-XN^7:
M;P>.W+F/\FR\8A0[+(:ZJ;G1+&H@6+I:A29L.?'CO,MR'?E3N.H2K;620,T(
M(S5M4+*D)4K9*BD;CN&P.P[MM@?16X_TT!!R43>RK*:K#<>O<JR"9'K:#&J6
MSR&XLI+A;8A4]+%<G64MY7:>C,=HD)'574#51,#@7G3C[R1XIPOFGBFZ_<''
MF?U2[?&;A<9Z"_.AMON1'%.0GTI>BOLRF'$*0L`CMW^.B*9NO_7_`+G1$M$0
M.?,(V.1>2^45[@5)8JJG'H$-LK6ZAAIRM9GI*(JE(;4%275^YU]"#KXA_F?R
M/)<QWUY3@]TZM&SC:FC&HQI4S.VA(M@X<XX%G7MOVOIT.,Z&MN3MH@7E6583
MD,VC(M^BR7''&*[TH89;<K\AC-LR6X#S8CP+IR,6^YB,#\Z9S3:!LG8AS?XZ
MZ7:CL_\`Y7REM=WEO"',1H^L;7%>&+TZ>F\1`(<AWU7X>HN?-G<FM7J/9U08
MDEC*!\?$Q)^8/DRM4GBNC;8O&')E9$LLCHH3M?6/.1Q(J[`OI7.ARPOVU-%)
M25)))(20D^FVO;*S[0=,"TO+>E4M+?G^0LX2M;21,*E"7TFG,D["<-SMD6SQ
M7&%3JF_K-<^V?8H5=N.&^.A'D0S-GFHTY#X@BUJ$KEN(KZ:LC-P(9:C),C(9
MH82Z^Y`:[O:6E;ZB%.;=H'PUQ5W?[+V'"\;9W=8`4[:B(50`2:U0`;O9B/41
M&;[L?W+RG@NIZE:?V]$/>5I$D?\`C`.#OXC%4/S;'9=6\W8)B.Q&FWVWV&D)
M+;Z5IDM+C%$@E2G.Q2>I``'X:](.H^.YOISD:?)?;SHPA=1JPJ@"-04\/23F
M#'#S"YEX_D!R?&7%E7$93$8@',:@_/Q6P7@,M^7B&*3)/?[TC'ZIQXK4%K#B
MH;6Z2I("5C_[;==?T+]%SG+I'BYRG.I*5A0D92^H[J<2Y/S7I-RD1#DKBF`V
MVM,?H4\G5@D(]PM*/S=P[?\`:05)V5^(UY6`!DOP(-?W><IS#D+`L4\'>%I_
M9S'Y1)O)4]+2BX]2<28%7O7V9VLM#*TNH9LU,(A-$D!2W-A\=4@9ZHJ7_P!N
MEY%R+3CKF7Q*RIQVOO>(,FEY=B55/<#5A'QVSG*J<FK'&%;K":/)(8!2">T/
M[[#?0?S4(6S(E94VE2DJ!4>X!)W!WV*>HV_U_P`=]0*JO'E5A&+9UX]\V4^8
M8Y19#42N*LZ^IKKFKBSF5N,XU8K8<+C[:G6U1U@+0ILH<0I(*5#5#.Q5T\UK
M`?VT6*XG=YYY1W5QCU%<7&/XGQ1%I;2VIH$ZPJX[\S*0^JO<D,.O0#++""LM
MD*<"4E1.I$#VS/PDW[G4#ZHG'WWO'/B3.O!K/^4+C#\;8S[B6QHLEQ3+&*B#
M#NXWUUBU56-<]8PHS,^373H\K<LE2B'4)4DI5UU7W#`,5"`1M.(7@^P!SGR-
MS'X8WU+R-=VF5'B/DFQP#%+^UE29EJ_BZ*N!;0:N38O[O3D4GU7T[2EDK"`$
MJ)(U`)#ZE=&T5=/O*?<1Y9B<CXUX`^)EV[4<HY[+H:/DG,*1]0O($G*G68]1
M@%)*80IZHFR8+BI,^6DI=;8':@I))U4?1D43[?WVY^&_!WCJI@4U!595S7;0
MXUGR1S'D,9FVS._R28"_91XEM8.2YU;4P%/*::;:<'N)3W+*E'H8(,,\240R
MZJ8%W63*N]KH%U4S6E1K&KM(,2SK+"(Z%)6Q-@3&W(K\9:#^8E0((^&LMCY)
MBA-^.7@+'\1//WEGE;AG'(]-X^\^\3!R[J8JVHU3@G(U/?1YJ8%='$A3ZJ;(
MF'EOM-!/MQU@I2`"-;D($!AC\U7)S1>F5=J$I7ND^@"NU/<01W$=I[5!1/P]
M/PUD`#)1"'^[+R!E^5\?8;X0<.2VE<T>94^UQ.*YN3^V>,<:KWK;/,EF-(]Q
MP178T80D*';NJ3MOH03EDCP'UEE0+^W4\@K*+C_.OAYF<AV':<59"]E&&TT]
M:T2Z^J>F2*?-*AAAT!QF+49#$2OVQW%OWU;_``UK`CS4>)PB76SM&?\`?;#F
MP3W)2H`*!)!'11V]-_AK.JJ].JB"OY*,-O>4&<*<F,QNR/C?R/H<7N@T49*U
M-!HJ)4I)/P!Z:^)/Y0VU*X_*#F#7KBE3`L<@3G;0=P7!^07M9T!4F.WMM&V#
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MT2+3R41ZZSLJY=U^FIF-A0_3V$^\VVI))V60D`?$C7L1;=3\1SG3/(=0<5[=
M7BJ%P:=*YKTY5I4221(0@Q^N3G<8X!G*\*A85*'(4!(2-;^J(F(;CJY#$?JA
MO\SMPRX](1?*LGBXS[LA;$YI:5J6@((0L!L(<2>@0.P?AKY@=ZO:IU:\Y\G.
MZW5R?HV#UD/':SX9/\US_P!)RN(TI0J4A"UC&1^IV(<YZL?]:-7QND#!<*'4
M;8U5=5$*(`B-;#I\IWW]=M?=GH?V_P##.($?I_MMLW_J@O5'FW_O%T7=Z\S^
MI3NGO(8:6^\XAJ.RVMZ0XXL-MMQFT*<?D%710#+:"2-_37E;+M:UP_'/S6\8
MLV\\/*7R[YKY2J<8AXBI/C-XYU4^JO[%3F"8[*<E9IE[;E;53(Z?W#D"%,(4
M%[J:20O5"!I':,"A857.G&'B!]Y9KF/A#+&<FX(YGS2(]=SHL6?"KH]%RM)^
M@RJL2BS@P7%NTM]M,&R"A(6D#KML5$@0P&(6\9#<2ZE#K1#C#J/=;=2[WH6T
MZ2XTM!'12'4K[@1N-CM\-%,=5%/D&5?P7S1N1M_%&?=!_P#(8S9_$G<@`_AL
M=]1L=R?Q6G5]AGF'E+AR7Y/7?&'CWE_D0F3C''K]]6X;D&/T5KCL2M?RB2PE
M$;(Y,9=V_9ID*1'9C%2^YL@]"-2(CM].1*I?56IS_P`RLL^]9R;$\",9^E\/
MN.VIB,IY'=Y$>;MN6N0)6(3@S8X'B]+&;AUU1953CH>>;D.*<<"`>TA)&M[B
M_P`$&9^"V,O%GQFXN\1^(<4X.XCKWZ[%L8!<DRY:U2;C)+R8H.6F1WDWO)DS
MK)]LJ7U"6P0E([0-4R?/-9BVP$YD+4/\75*Y'^_E:V6=N.3I;//O+EDR)J&"
M'IV.ULB)0QULK:3VF%'2%(*>O;MZZR&#[LSDJ"0&T*WAF4$'O[NX*'7\OVR3
MN3N4[[?]M%-H!<+L=1W``=N^^^RNN^W7T]#HJNOZ9&P3N>T'<`';X]Q&^Q4I
M._P)VZ:@`&2+RO=L<%10E*&0MPO*.R64`>XXZXM:MDH2$[D[[C\"-535EKI\
M)^:OC-G'W#_)KR@YPY1I,:K>(FT>,GC3"F5=],$G'8C_`-;R5E\'].K9K3KM
MOD*?I?=2K?V&S\#IZLQ].JI<,?Z<70H<GYYXK\4?O&P?)#AG+XV5\'<HYK#L
M\BLZRNM*^)`I>45MT>>U[L>S8@/OJJ;UY$_O`"!OO\-1QN].11WQ&2WC:YYF
M3&:E17&WHDIIN5$=9*5M/17TAR.ZAQ`"5)6TH;=2=NN^KYZHLAHB![Y4SC7>
M3^<O.-I=:^CQ=?8ZV0RT?T6.A+KQ.Y>:420`G;<CKKX:?ES7'&?DMS'*TS4J
M3A&R)IL\<+>GD_Q&2]M>VE&57H2WC$AFKDMF#N+*7.+N434U\5=G8J<K`"U6
M8I5^W#;MWUL]K`N%'M4J(E#A7LHJ422GTZ:Y6[3=Z*UO;4Y]01KBG0C'VK:V
M,`+R4_Z;AO5LC,ZC#%EXGU7TU2K70IVT1"HXE*O+$B(`P#X$^>:=4[BOB=^7
M<W<&7DV+)KJR!;9'18]+C.U*9TY:%RJVN<EMN/1D-K<W4E&R0L$#IKSBIVM[
M,3Y/D^3X^OR7'<C6IQNN4M;.I3C;_<U0!*C"4@P+2&\-C(%=LM>K>H>/H4^/
MK4Z5>C*J8T*LP?<`B&]0&!QR?1DX,@S*FQ.M&+8J\O'6XS;4['+>+(#C5_!F
MLJ=:8R(RR^DRY!)`61[:3TV]-=WZMZVZ7Z/XO_!>D:D^+Y&VI1E82IS>A6HG
MU2ER$Y$PG4Q+`@C1EVKC^(N.7O(\AR`)E.H?<`BQ!!;T9%FQ0^>3<I_6E/\`
MOQRU8%_9R6CMCH6%O-J0AIA"0@]Q/;W!([O7;7SL[D]16_/U+B5QLG/[L"4Z
M8#2F)1WF(``VDY,&&BY\XCAJ%A;3C&9^VE2+!SZ<-2^9U\T>#CPK1@>&'YD]
MN-U/N!?;N$B$VH@*5M\P]-AK^@GH%ZG1'#REB/[;;^7_`&HKTUYD@<O<Q8!J
MTOT?/YH?7W8/)ZT\<O$G(F,/D%7*_.5O7<'<21`4-SADV?.?HR[-A`/<I%1!
MD+=*@E6QVW(WUY@7&"[7*40?)6`\/?%W!O&SQHXAX:8HJ.RFXCB-:G);&?50
M'Y]SEUFRBRR2WER)+;JW)4JV?<*MSU[1^&L[I;F/@AC&0QR0?_[AWQE;RCQO
MP'R`PS'X<6UX3RY$?*GJNOCQY0P?)RW$<>4B`ED/L5=RU'>!5_1U((UI&"(K
M]J'R85Y/^$_$>66MM%GY[AE4CC3D4(>0[(8R3$8Z8#$V<UW^XP[;U*8S_P"9
MN"M2MCJ`2)?1:)5R.?U)_@KF;N<2I0XISY)*E=B-AC%@5+W6L(`Z^N^V_P`=
M')+?T_S6<7\EJ^_VQQ*LC\MDES9(QKB%*2"WWI<$O+T;A`=4#VN#8$_[AT/K
MOTZ,91C+=_M%OA@JS%>G[WWAMDWCURSB7W&_&GWL5E#*Z:;R5,HT+C'$.1&'
MDFCY%6TPGY:G)TM_16H(+;BU`KW#FMQB3/\`W4Q&(\&1V_MR^;F,^='CUC_)
M$(IJ\]Q[V<6Y6Q0]GO4F:U\5H3Y33:=BY37!_P#(BNA(0I"]@?AJ^DRPT488
M-HM<#[H7$.>_;V^XW@OG5AE+86G%^:\@UV?B77LK1!K,A;0U!SS#;24`\U7.
M74!:I$-QSL;=([-]^FJ?5GHJ7.JVX.%.;<`\@>,L6Y<XNR"%D.'9=51;2!*A
MRF)"V)#Z$F156#:?S8-C7OE3;C:]NTIWVV.B*6GG24GL5\X^;M*00-B`ION/
M:`I1.P.YZ_#1%0WG3S4B\=^3WCAXGX!`I,WY3YDR&;*S6M?LG4N<;<8T]<[8
M664VD:"%E$V6I*6HC3JD>X0I7;MJB40&(<HSIH_=.\F[#QD\0L]N<6DH7RER
M:N%Q%Q#6MK;9GR<TSQW]!AR8R?E6H5;,Q4A2P"$J2`=M3/%F"8$98A2?X1^+
MF+>-OBKPIP_8T%'9Y'CF(PI>76]A40)$VSSN^2JXR>SE/2$///R7KB<XV5[E
M1"!Z:%V9\"IN.6B%?_<&^+=;GOBUCO/.*TU;#R'@')-KHUU>RRM_!\R7'J+1
MX*AI94G]%L$QWT*4"$[*.XVWU``%`1'(*[OV@O*7_P#3OA'QE:V,\3,\XSC_
M`,6<@AU\29AM<50(T"VE;A+O;=4J&9"5'9)*CL5;:'')5WRP13>\>U[G=\O;
MW=VWPVWW[?\`+555#/+OQCL.5GV<ZP1+'[WJH?T4NJ?=,6-D4%`"HG<^E2?;
MG0'%;H4=P4@)/37I'^6'XR7_`'BM:?4G15Q2LNJ+=Q6W1!^YA"(,8OI(!@#F
MP;1<I]N>OSTM<&SO9?\`SY.&+'ZL\\ODAV5W'G-F-6ZF9O&67N&*4MJ;16NN
MM+>1W;RFW&'%(6%.)!24[`I_SU\SK;M;WJX3FJ=>?3O-3J4"0?:IG:2&#@Q`
M)C)A(`^*Y]N.INB>4HQK1NJ<3.+$%BWDQR3Y@IYO1&M&G./L[2+*/[;Q1322
M74)DA\-K4I6Y4XM6Y5V[[';7E5KQ7?JVE?UJ?2?/^W=AF^WJ,98>HA\W`+YY
M^)7::L^BZTX>U>T`:1<$RU9O'P37O,:YHL8S;`XVS-88;2RE*:F2LB-\ZT(:
M6M:5!<=7P]`1KL'+]#]]>9L/;K=(\Y4O(AB)6]2(EN.XN78[2<!H,%^^VYGH
M^VE*<+RA[DF<D@G##!\ODI,X2\2.1L\RNLN^0:JPQO":N;'G3&[979?7S\<H
MD(C,Q-S]/'$E(#JR>Y0].FN<^PGXB]9<WU5;=2=QK:=OT?2`W6T@8U?<S]3>
MH",LO$9KQ7K7N5QG'\;/B^$J0K5ZL6EM;(^$OVQ1@Y-;+-+-K*>4U3S#7RX=
M;.#'U2*N4J-[$26B,[LV\B&\$J+>^SFVWIK[!65K1L+>E8V@VV=&`A`>$8AA
M^Y>L528G4-2HYF2Y^:#!SA]GG)/)[-<<Y-Y^\WN9\GSK"9:)O'*Z''\3QS&<
M(L(\KZN-,I<<CQ'&$S4N)3[CZC[JPG8D#7[R=8X*.,PBB\$\<\L\;8E+H.6.
M:+'G.Z^N;-5E-CC%-C,V)5HCML-09L6F2B+.?#C?N*D+'>HJ.^NF')W2S4=U
M5_S'\(^3_,"+D&`6_E/EW&O!>75E9!O>,L0PW&7)UA](XIZ4F1EU@T[8N1IC
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M5C67&5"$2=9JK(P^CK7BX0\VEH)]IW8H((&KN$<6Q6B01AD@Z<#_`&.D^,>4
MVN><`>:W.G&^5RY$B/&145^-R<9DT3CRWJRBR2@F1WHN1,5S92E#CWYFR?ZN
MIUD,7,<'49D79'!\7.>$VN'/(J=5<],V-,NJS.VO\;KZ>-E+BE+`FFE@@1:B
M6T".U;&R@4@@C5#NVB;@,\T-#`OM*9?XK9=;Y5X)^6O('"5-?3'9MEP[G5-"
MY.XGF/*42E":FP=8G5W:@E/NM.!S;X]-:T3<)98*?;KA'[E^;U<J@NO,'B/C
M>+,BEI[).,.$PYE;/^U7T3V3W-A`B%:=R%I;[D$]-9+Z(H\\6/M)\?\`C!SA
M<^2@YOY?Y9YNR#'+ZDGY9R1*K+&.Y97[2FI%RB(Q'#R5LD[LL^Y[:4#8;:!Q
MFC#YJ.>>OL^95Y49=09]S]YO<UY+D^%SU6N`0\=H,3QS%,*FID-R(\NFH6(J
MVA-9=8;*GUJ4\KL]1N=:,B<"S*1,L1)B$3/@;C'ESC?%IU#R]SC8\[V@G-.T
MF3VV(T>+3ZZJ9AML(@S&Z!+3=A,4ZCW%2%I]PE1W]='6G\`JY^8/A5RAY;UV
M4\=2?*/+.,>",SIZRHR;C;$\/QI^PL68S@?F,'+;)IVQ:AV+J$*4V@;`I_Q.
MH^+G)'^"ISP+]E>R\2LDD9?XP^;?.7'EI9M,Q<CJ[6FQ7)<5RF(QLB,B[QV9
M%1$>D1$DI9=2$N-]-CTU7Q<9+()<NR,)^S^2?X:_97\HN?RE^T/T;^6_VU6>
M[^YOIO:_=7[6W_2N_P!_\SZ7_B^'IJ/BZJE5;*5$JZA1V.^Y&VVPZ?AN!K!I
MP)!;*3_$LV/C@F&H!^*ZTQD)```';ML1N5="#ZG\=M4FJ^!++.T.X)'P*Y*9
M!Z@`'8]?CUV^/^@TW5?'!U=H\W^)7#V%;>J`/B.T;^I)._7J=]!*J"[IMBS:
M+Y],E0)[0A2CNL@G<['\>IV(U(P$8D##<7+:E00C'Z<"OKZ`&R`-@0$`[$]2
M4[>G5(Z>O^.MK6:J3R/GN8K\@L"XTQ[+(]%CK%)(S;D<K8B,_0TD-[Z:%&-R
M^H)CFTD$)[5]I(]#JB)$,#@ZK$JU4:<RXUWM/,NMN!3Z'$.)4R6"GO#I<2I2
M/;"4GJ#MH(EL2%&;!1O@C_(4J\S>?D][A][ACUPW_'J<8!5,@5;;1;FP\AE)
M<=8ESTR%;@H_I'0]="&+%,&\U("+ZM58JJ!.@_J[;*GEU7U\;]13'20I+_T/
MN?4^RM(_J*>G^6HLAQ@4V.1,]Q_C3$;_`#O*WI$.AQN`Y)LUPVOJ)"F^]E#3
M$=ON;*Y+K[B4-I'J2=9,BXCHNI&)D0/)9S'<HJLHIJV[I9#<VNL8K4IIQF0Q
M(<;#C33OT\CV7'$-S$>\$K;*@I)W_#6B""VBSE@?%5IY#SO,D>1?&W'>-97#
MI\39QJPSGD9ER-";7%I*]]4&O+]N^H>Q$MI&X["0/R]];!CM\T))*M1&L(\Q
MEB7`>B/P9+:W&WX\AE]E]':"'8[["ELN)Z^NY&L8A%YK*_KJ9A4BSF0*Z.VE
M*G'Y\Z-#9;0XL(0I3LAQL);[B/FVZD@#3:_J1L,5Z7[BOBL&7+E1HD'L;49L
MN0U'C*#H'M$//*0@I="AV'NW5OT&H'EEHH^+,NMN[KGGW(L>;#DRV&FW9$1J
M5&<F1VGDE;+C\5#BGT(<'5.X`4/CK1!&>*K$9KB]>UK+ST=Z;7,RF&#+DQG[
M"*T]'A#8?62FU+]R/&[CT4O9._0'449=*,EHEH@K1;U2DVBRFK4FT@J1:J2K
M;M@.!TIE[D[?E@]=P>NJ0S*K)"6!ONV0KO`[04EUQ925+'M@$@]#M^('3TU-
M%-5X1?UJYZ*E$ZM<LG6E/)KT3XJYJF4%`6\F*EPO&,WW[*5M\IU,RWDJLRA:
M'"I/7=.XV._S#<I"QT&X)!V.J,`R,N[1$M$2T1+1$M$7Q6^Q[1N?A^&_^.B+
M%SY:($67.F.)3$AQ'Y4I(1NI+,9E3SR@H'?;L1OJ:H[EM4)Z#%B\D4O*'+N2
M,KRK)N;;:QP[B3CB)(6LMUM8^Y65EW<)BNI>9B0%`R=UD-M)3N05$:I&6:$,
M<<U:WDIQC@SQMJZF[LYLZUHJ"AQ6K5&L?HW<CRN8/I(=6]*60Z:UR<YLZK?N
M6RGKMN=2)B/3BZ+&X>W_``1XF7%M0!-O>46/WN364EL/.PI.8SRJ7.=BMOJ]
MQ5/#G+2A*DG8ML]/CK1#%CB@9WU4)5-%)8O_`!>PV@N3?<P7%JSS-R]G'U#D
MJPC8T_5N/SXUG/0I0CP+'ZUN'#AK(0H,[@;C<M'5)!^*EOR6BUW(/+O`_#2I
M:_I+&YLL[SVN>LE,5SV#XLEN2F/90RH(DMV5H&FT%?1`W/IH)D`P#,FR1CO!
MR_@N[Q@JFW>1O(C,L=C?I?%=UEU9187`:6MFFFRL4B&NR2]IXZU?3MP7IC82
M'FMDND$]=M9&&`R4].8=]5%>)C$\URSGOR,Y$FL2<*<7;XEA.(&8VI[*Z/!/
M>K`^W";<;=M(5A9CMBQV_D+Z^Y6^^KM(#A3%_)2A@<^?XU>*M3;9#&D2K]<A
M4Z!33Y2FF(-MFMH'**BDN/J_\*NKFY2`Z`>UM#9'QT$I2^K-7+`*'<FD8QR#
MRC@/%-O>_NE^NMX'(7,672)CST!^<2VY08'B\..X6ETZK)8[T!*F^QL$G??5
M].9S5*EGS0K9.24^`\98\])&8<BY+#H*BK:D._0P*J`^U-M<C5%8*>UZJB-`
M-N?T)]-M]0XH"P;Q5@L*X:X_XXD2LIKF'1D4G'8]-D>63;*2^]/BU:4]\R<9
M+I80MHI4H$`=J1MZ:R7&`40Z+.772YO*_/RQ96V,WKKG$7#N+.6<A^7RIE+D
ME<%RULTI<29=.W9$N,M(V2A+7=UVUU!`R\F19O`>.*.HY!X<X<N;Q<NYXH^E
MSW/;@R9+CL?(;K=S'^/<5;9<7]-71I+JW92"D@I3N2-QJ$DX'1%;+F'DUEG-
M6^+D9$QB5=#Q:7G/(^0L2!'N(V*Q'0RS08L`3(<NKETJ"G$A2VV@=MM]:B`0
M0<U/-1_XEQL=S;+^0^:&8T>&YE1C4N#4I6Y(E4&`5'O1XTR>\MUY*+;(I25N
MNI!W4E"2=9,3$NJZORVA+8[4#8`^FY.WQV!/78;_`.FHBYZ(EHB6B):(EHB7
M_KHB\C\1J0E3;B`MI86EUM75+J%H*%M.)(V6VXA1!!W&VC(H_P`/XFP#`G9\
MO#\/I,?F63SK\MZ&A]3BEON%Q\,N///*B-.K.Y0R4(W^&BBS.48'BF;1(4#+
ML?K<A@UUBQ;P8EDT7V8]G&.\>:A)4G=YK<[;[@:SB_DA?19MZHA2(*ZMV'$5
M6NQE0GX"X[2X3L%;:FG(:HI'LF.MI7:4[=NQ]-4!@R8ZYIKXMQOAN!QYR<.Q
MFOI'9Y0J6N&DN2Y084/887,FNO/F.RA.S;96&FO@D:`R;U*LJ\8SP=9YIRSR
MUR-S+B,4QKA=!C?'M<JYCRG8&)TK#KK\HRJ6<)$5ZSL7U*=94H=R=@H$:N62
M2`?=%WR\E:B)0P*^N8IZZO@P:B+$;@1ZZ.RAJ,U#2CVU1VV$`,M)*2=]AN?4
MG?3SU4`8)E-\-<:,RL7F,8-CJ)&%MRF<74J)NU1LSG%/S1"8[U,E;[^RR7$*
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M].\`]"#J$$YHLGA^#8Q@=6S18E15M!3,?\%?5QT1V&=M]E%1[GWW?FV[EJ.R
M0`/35.[1$\-5$M$2T1+1$M$2T1+1$M$2T1+1$M$2T1+1$M$2T1+1$M$2T1+1
/$M$2T1+1$M$2T1+1%__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g676869g91g31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g676869g91g31.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%(`V`,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/?Z`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"
M@`H`*`"@`H`*`"@`H`9+*D,3RR':B`L3Z"IG)0BY2V0TFW9'%ZEXEN[F9DM'
M,$`.`5^\WOGM7S&)S.K4E:F[+\3TJ>'C%>]JRE'=ZE)G%]<\#/\`K6_QKC6(
MQ#VF_O9HX4UT1,)]1,;-]MN>"/\`EJW^-6JV(M?G?WL7+3[(C>ZU)%W?;KGV
M_>M_C4/$8A*[F_O8U"GV0^S\0:C9R`O,TT?=9#G/X]:VHYA7I/5W7F3.A"2V
ML=Q9W<=[:1W$1^1QGZ>U?54:L:T%..S/,G%PERLGK4D*`,7Q/XDMO"^DB^N(
MS+EPBQJ<%B>OY#)I-V&E<UH9H[B".:)@T<BAE([@C(IB)*`,S6-6ETI(WCTN
M\OE;.[[,H8ICU!(_2D,Y5OBSH4;F-[/4$D4[2AA`(/I]ZE<?*:7_``FDOE^=
M_P`(OK7DXSN\@=/7&[-.XK%K0_&NB:_-]GM+EH[K_GA,NQ_P'?\`"BX6L=#3
M$-=TC1G=@B*,EF.`!0!R<_Q!TU[TV6CVMUJ]R.HM4^4?5CQ2N.Q,^O\`B1(O
M-/A"0KUVK>QEORHU"R,VV^)UD^JQ:;>Z3?65T\BQ[9`ORDG`SSTI7'8[JJ)"
M@#%\3^([?POI/VZXC,N75$C4X+$_X#)I-V&E<UH)H[FWCGB;='(H=3Z@C(IB
M)*`"@#+\1DKH%U@XX4?^/"N#,7;"R^7YHWP_\1'$6T+,0P'%?)1BV[GIMV-Z
MQL0^V:%=Q4_/'W_#U%>I0H7M.'3='-.=M&7S80*D\*2IEF&WGH/>NQX>"4H*
M2W5C+VDM&T5[W3E!+'Y((P%4]V^E8U\,D[O2*T]2H5.G4YZY@))*KA1^0KQY
MQ=[I'7%G4>$2?[*D4G@2G'Y"OH\H=Z#]3@Q7QF_7KG*%`'DOQ#6Z\176HM:M
MFST)%W@?QR,?F_(5+*6ATGPOUG^TO"JVDC9FL6\H_P"[U7_#\*$)G;50@H`\
M)\0JH^+3#`P;V+(_[YJ.I:V/=JL@\,^)D*Z9XX%S9GR97C2?*<8?)Y_05#W+
M6Q[5IT[W.F6EQ(-LDL2NP]"0":H@\D\:>(;WQ5XE3PUI4A6U$HA.#Q*^>2?]
MD<_E4O4M*QZ?X?T"Q\.:9'9648&!^\D(^:1O4U6Q+9JTQ',>,_#"Z[81W%K$
MO]J6KK)`^=I.#DJ3Z?UI-#3L=,I)4%A@XY'I3$+0!Y-\0UNO$5UJ)M6S9Z%&
MID`_CD8_-^2U+*6AT7PNUG^TO"PM)&S-8MY9_P!P\K_4?A0A,[>J$%`&7XC_
M`.0#<_\``?\`T(5Y^9?[K+Y?FC?#_P`1'*Z>A#`K,B'U+8KYO#QUNG8]";\C
M;OIVM]-WJT1D=@A>/@@'KG\J]6O-TZ',FKO2Z.6$>:=A^FO"J#=BEA907Q!4
M3Z%OS(Y!(H\O"<J9.@S74I1DFM--KF=FK'/:DC,Q+SQO]#T_"O'Q*;>LDSKI
MNVR-?PF,:;-_UU/\A7K91_`?J<V*^-&_7L'(9NOZM'H6A7FHR8Q!&2H_O-T4
M?GBEL-&#X1LK.V\(B"_N86N-0#376Z09)?J#^%)`]S@?`EXWAGQ_+I<L@,,S
MM;%@<@D'Y#_GUI+1E/8]NJR`H`\&\42B#XJ32E'<)=Q-M098X"\`=S4=2UL>
MAZC\3M'TW*366HI/C(BDMS&3^=.Y-C(TSPG<^,M:3Q/KCQ+9R[6@M8GW94?=
M#'T]1]>E%KCO;0]#U&9K72KN:,8:*%V7'LI(IDGBWPJA6X\:"63EHX'<$^IP
M,_J:E%O8]SJR`H`*`"@#.U[5H]#T.[U&7I!&2H_O-T`_$XI;#1@>$+.TMO"7
ME:A<P-<:B&FNMT@R2_8_A20/<X'P-=GPQ\0)=+ED!AF=K8L#D$Y^0_Y]:2T9
M3V/;JL@*`,KQ)QH%S_P'_P!"%>?F7^ZR^7YHWP_\1'(64L:$%@6]@<5\O2E&
M+U/1DGT.B1XKJP:*X58X7X1$'S$^M>S&4*E)QJ*R>R6_J<C3C*\=RL-(NX'9
M5NX3&A`+'((_"L?J52#:4U9%^VB^A>`%G!)#&PDG!S('7[X]JZM*,7"+O+K?
MKZ&7QM-['/7T\<A)5-A]`<BO&K3C+96.R":-[PB<Z9+_`-=3_(5[F4?P'ZG'
MBOC1T%>P<AP?BYO^$@\6:3X73YK=&^U7@_V1T4_Y[BI?8I:*YO?\(5X9_P"@
M'9_]^Q3LA79YG\2_#T/A_5+'4-+@6V@D&`L8P%D4Y!_+^52U8I,]8T#54UK0
M;+44_P"6T8+#T;H1^>:I$O0TJ8CPKQ#_`,E;/_7[%_[+4=2^AZGXR\,Q>)M#
MDMP%%W%\]O(>S>GT/2J:)3L>??#;Q1)HVIOX>U,F.&60K'O_`.64O=3['^?U
MJ4RFCV":)9H9(G&4=2I'L:L@\'\-RMX-^(B6][\B1R-;R,>!M;HWTZ&H6C+W
M1[W5D!0`V1TBC:1V"H@+,3T`%`%;3-1M]6TZ&^M2Q@F!*%EP2,XSBD&QQWB]
M_P"W_%6D>%D^:`-]JO`/[@Z`_P">XI/L4M-3>_X0KPS_`-`.S_[]BG9"NSS/
MXE^'8-`U*QU#2X%MH)!C$8P%D4Y!_+^52U8I,]8\/ZJFMZ#9:BF,S1@L!V;H
MP_/-42]#2IB*>JVAO=+N+=?O.OR_4<C^5<V*I.M1E!=32E+DFF>>%9+6=HY4
M*NAPRGL:^,E&4)6DM4>NFI*Z+]K?%)1(QR5Y&?7M6].LXRYGT,Y0NK%I=1/V
M>52V2S`G]:V6(?))/K8CV>J(+F_,BHV?G4;2?IT-95*[E9]2HPMH9LTQE;/<
M_K7,VY.[-4K'=>'K)['2D648D<ER/3-?6Y?1=&@E+=ZGEUYJ<]!FMZY)I("0
M:3?7\[+N5;>+*_0MVKOV,4C@O"UWK>F>(]3U?6_#VHO)>@8DAAW>6`?NX].G
MY4D-GJ43^;$D@5EW*#M88(SZCUJB3S_X@W%QKFE2:39:#J4\\<P(F\C$8QU(
M/?(J64M#*\$7_B/PO`]C?^'=0FL6;>IBBRT9/7CN*%H#U._O/$(M+&VN5TK4
MIS<*2L45N2Z8[,/X:8K'D>I:;XFO_%KZZGAR\0&=95B*=EQ@'\JDH]<T;7GU
M5S%+I&H6$JIN/VF':OT#=ZHFUCA?B5X+N;F\CUG2+5Y99"%GBB7+9[.!^A_"
MDT-,V/#WBG7;;3XK;7?#FIM)&H7[1%#OWCU8=<T)A8N^,?!%KXKMTN(F%MJ"
M+A)"O##^ZP_SBFU<2=C(T77O$7A:%=.\1Z1=7-M$-L=Y;+YN%[`XZ_SI;#LF
M;W_"?:%LRCW;O_SS6TD+?EMIW%8Y7Q1J_BGQ3:-8:-H-[;6,G#RS+L>0>G/0
M4G=C5D=;+J#^&-&L;"WTF]OIH[=55;:+*Y`QRW0<T]A;G&^%[O6]-\2ZEK&M
M^'M1=[U<!X8=WE@'[N/3&/RI(;/4XI/-A20*RAU#;6&",]B.QIDG`?$&XN-;
MTJ72++0=2GG28$3>1B,8ZD'OD4F4M#)\#WWB+PO"]CJ'A[4);!VWJT<66C/?
MCN#0M`>IZI;S">WBF".@D4,%==K+D9P1V-4224`4;[2++4,&XA!<='4X/YUR
MU\)1KZS6IK"K.&S*'_"):<.C3_\`??\`]:N/^R</Y_>:_6IB_P#"*:?C&^?_
M`+['^%']DX?N_O#ZU,3_`(1/3O[\_P#WW_\`6H_LG#^?WA]:F6K/0-/L9!)'
M"6D'1G.<5T4<!0HOFBM?,SG7G-6;-.NXQ$)"@DG`'4F@"&WO;>[:06\JR>6<
M,5Y`/UI#M8GIB(XIHITWPR+(N<94Y%("2F`4`%`",P12S$!1R2>U`$-M>6]W
MO^SRB0(<,5Z9^M(=K$],04`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`
M%74KM;'3I[AOX%X'J>PI;#1CZ)>6]C#:V120RW!+&4+\A?J1GOZ4D-HV+Z^@
ML+=I)LD`$[5&213V$E<33DMH["-[6$00R#S-N,8SZT(&0#6K8X=5<VYD\L38
M^4M[=\>]%PL7;BYBM(&FF<*B]Z-A&-IVN2,D)OXG07,A$+A1MQV'K23*:[&I
MJ-RMGIT]PW\"$@>I[4]A(Q=+U"WTK3;:.2.1O-?YY57Y0[=LTD[#:N=&2`,D
MX`JB3.GUF"%X42.64S/L0JO#'V)I7'8LWM]%80&67<<`D*HR3BC8$KE6#6X+
MB6W2*&8B8??V?*IQG!-%PM8EU'5;?34!E#L<CA!G&?6B]@2N0MKUHMVD#+*`
MZED<KPWT[FBX6)[#4H]0,ZI')&T+;6#C!S1<&K%B>XCMPN\G<W"JHR6^@H$5
M['4DOY)UCBD586VEG&,GN/PHN-JQ=IB"@`H`*`"@`H`*`"@`H`P/$#QRWMA9
MW#^7:LQDD8]#CH*EE(M06YO;^*Z,9CM;=2($(P23U;'8>E,6Q5UR47%];:=M
M8JW[R0*.6`Z*/J:3&BYK8F&A7`@4A]@&%[#O^E-["6Y0EA6]^P:99\VUOM>:
M1?NC'09]32\A[:ECQ+<>7IZVRMA[EPF?1>YH81(Y;=+^^L;>VYM++YG<="1T
M4>M`;$FO*;R2TTY<A97WR$=D6A@M-1C+;ZN;*&S'^AV[[W.T@<=%YHW#8DUF
M[5+RSLY=P@E):3:"=P'1>/4T,$BI8SO?^(9))(6"VW[N*/'W/5C1U#9%OQ!Y
MD\4&GP@^9<OM+8^ZHY-#!&I;V\=K;QP1+M1!@"F28M[$NJZT('&+.S&^4X^^
MW8?E2W92T14\PK%=:_+&=W^KM4(^Z.@-'F/R-?0X!;Z:HVMN8[F<]7)ZFFB6
M8_\`;#"RO+]$9KLL4!*G$*YP!_6E<JW0VM#A$&F1H%;U+-U<GJ::)9HTQ!0`
M4`%`!0`4`%`!0`4`(5!QD`XH`6@!,#.<<T`+0`@`484`#T%`&-Y%W<>(([F>
MS=;>)"L>74X)ZDC-3U*Z&R`%&``!Z"J)%H`0``8`P*`#`R#CD4```'08H`6@
M`H`*`$(!&",B@!:`$VKC&!CTQ0`M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`
>4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
